The expression of endogenous retroviruses in tumors appears to be a major mechanism of immunogenicity and can predict responses to PD-1 blockade in clear-cell renal cell carcinoma, according to a new study.
Experts discussed how as the field of immunotherapy matures, new targets, combinations, and concepts have begun to emerge, with particular interest in expanding the uses of immunotherapy into malignancies that have so far proven largely resistant to the approach.
A novel approach to CAR T-cell therapy involving a trivalent design targeting CD19, CD20, and CD22 can effectively target primary acute lymphoblastic leukemia (ALL) cells, and could potentially mitigate CD19-negative relapse, according to a new laboratory study.
The combination of a selective PARP inhibitor known as pamiparib (BGB-290) and an agent targeting the PD-1 receptor known as tislelizumab (BGB-A317) was well tolerated with activity that supports continued investigation, according to a phase I trial in patients with advanced malignancies.
A first-in-class agent known as E7046 that inhibits the PGE2-receptor type 4 was well tolerated and showed promising clinical activity, especially regarding its potential for combination therapy, in a phase I trial of patients with advanced malignancies.
Treatment with multisite stereotactic body radiotherapy prior to pembrolizumab treatment may help improve outcomes in patients with advanced solid tumors and multiple metastatic sites, according to a phase I study.
Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit.
ASCO's TAPUR Study continues to expand and now has more than 450 participants enrolled on study drug, new partnerships, and a revised protocol to lower the age of eligibility, and will soon have more than 100 sites.
Dr. Jeffrey A. Bluestone, president and CEO of the Parker Institute for Cancer Immunotherapy, will provide an overview of past developments in cancer immunotherapy and discuss the future of research in this field in his keynote lecture on January 25.
Internationally renowned clinical scientist Malcolm K. Brenner, MD, PhD, will provide an overview of recent advances in the development of cellular therapies for cancer during his keynote lecture, “Cellular Therapy for Cancer.”